The HMH Emerge Program, a partnership between Hackensack Meridian Health (HMH) and Choose New Jersey, has announced the winners of its 2025 pitch competition. The initiative is designed to help global health technology startups enter and expand in the United States, specifically by establishing operations in New Jersey.
Three companies were chosen as winners by the HMH Emerge Board of Directors for their solutions aimed at cardiovascular health challenges. These startups will receive financial assistance, support for clinical trials or studies, business model guidance, and opportunities for internal pilot programs to strengthen their presence in the US healthcare market.
Ihor Sawczuk, M.D., FACS, president of Academics, Research and Innovation at Hackensack Meridian Health, commented on the selection: “The three companies selected by HMH Emerge have packaged innovative products with aligning missions and values to address issues in cardiovascular health care. We’re eager to witness the potential of these groups in the marketplace, while most importantly observing their impact on improving patient care in a clinical environment.”
Choose New Jersey plays a role by linking international entrepreneurs with resources available within New Jersey’s healthcare sector. Bill Noonan, chief business development officer at Choose New Jersey, stated: “The magnitude of technological innovation and patient-centric focus presented throughout the competition has been nothing short of incredible. We are honored to provide service and guidance to these companies as they establish or expand US operations and integrate into New Jersey’s healthcare and life sciences ecosystem.”
Each winning company receives tailored support based on individual needs regarding partnership level, pilot depth, and investment size. The program also maintains strict confidentiality through non-disclosure agreements to protect intellectual property.
In 2024, two Ireland-based firms—Spiorad and Neurobell—were chosen for their innovations in cardiovascular and neurological technologies. Those collaborations continue alongside new relationships formed with this year’s winners.
Sandra Powell-Elliott, chief innovation officer for Hackensack Meridian Health who leads its Office of Innovation and Commercialization, remarked: “For the second year since its inception, HMH Emerge is fostering new ideas and innovations, weighing both market and clinical value. The discussions have been invaluable for all parties involved, and help our colleagues overseas gain a foothold in the American market.”
